Man

OMAR LOZANO GARCIA

Principal investigator

Institute for Obesity Research

México, México

Líneas de Investigación


Development of novel strategies for medical and biomedical applications through nanotechnology. Research activities: Development of novel strategies for medical and biomedical applications through nanotechnology. Machine learning of biological system

Educación

  •  Física, UNIVERSITY OF HOUSTON. Estados Unidos, 2009
  •  Física, UNIVERSITY OF HOUSTON. Estados Unidos, 2006
  •  B. S. in Physics engineering, INSTITUTO TECNOLOGICO DE MONTERREY. México, 2004

Experiencia Profesional

  •   Professor Researcher Full Time

    Institute for Obesity Research

    Monterrey, México

    2018 - A la fecha

  •   Principal investigator, Bioengineering and medical devices unit Full Time

    Institute for Obesity Research

    Monterrey, México

    2021 - A la fecha

  •   Leader, Bioengineering and medical devices unit Full Time

    Institute for Obesity Research

    Monterrey, México

    2024 - A la fecha

Formación de Capital Humano


Current (at Tecnológico de Monterrey)

1. Azazel Monserrat Contreras Sanchez. Ph.D. Biomedical Sciences.
2. Mayte Rueda Munguía. Ph.D. Biomedical Sciences.
3. Ahmed Mohamed Agiba. Ph.D. Nanotechnology.
4. Aneliza Flores Villareal. Ph.D. Biotechnology.
5. Mario Adrián Tienda Vázquez. PhD. Nanotechnology.
6. Lorena Cuevas Guillermin. M.Sc. Biomedical Sciences.
7. Axel Reyes Molina. M.Sc. Nanotechnology.

Advised (at Tecnológico de Monterrey):

8. Azazel Monserrat Contreras Sanchez. M.Sc. Biomedical Sciences.
9. José María Gómez Cantú. M.Sc. Biomedical Sciences.
10. Agustín Arias Leñero. B.Sc. Nanotechnology and Chemical Sciences.
11. Héctor E. Flores Hernádez. M.Sc. Nanotechnology.
12. Hilda Beatriz Sánchez Madrigal. B.Sc. Nanotechnology and Chemical Sciences.
13. Azazel Monserrat Contreras Sanchez. B.Sc. Nanotechnology and Chemical Sciences.
14. Judith Bernal Ramírez, Ph.D. Biotechnology.
15. Paulina Hernández Fontes. M.Sc. Biomedical Sciences.
16. José María Gómez Cantú. B.Sc. Nanotechnology and Chemical Sciences.
17. Héctor E. Flores Hernández. B.Sc. Nanotechnology and Chemical Sciences.
18. Kevin Stalin Catzim Rios. B.Sc. Nanotechnology and Chemical Sciences.
19. Paola García Medina. B.Sc. Nanotechnology and Chemical Sciences.
20. Anay F. Lázaro Alfaro. M.Sc. Biotechnology.
21. Jesús Roberto Garza López. M.Sc. Biotechnology.


Premios y Distinciones

  •   “Premio al emprendimiento en Salud”

    IncMty

    México, 2016

    2nd prize winner at Healthaton 2016 “Premio al emprendimiento en Salud” within the framework of IncMty 2016. Monterrey, Mexico.

  •   Creación de empresas de Base Tecnológica en TecSalud

    INSTITUTO TECNOLOGICO DE MONTERREY

    Chile, 2020

    1st prize winner at Creación de empresas de Base Tecnológica en TecSalud. Monterrey, Mexico.

  •   Health Pioneers 2022-2023

    INSTITUTO TECNOLOGICO DE MONTERREY

    Chile, 2022

    2nd prize winner at Health Pioneers 2022-2023. Monterrey, México

  •   Health Pioneers 2023

    INSTITUTO TECNOLOGICO DE MONTERREY

    Chile, 2023

    1st prize winner at Health Pioneers 2023. Monterrey, México


 

Article (15)

Distinguishing pathophysiological features of heart failure with reduced and preserved ejection fraction: A comparative analysis of two mouse models
Mitochondrial Ca2þ Uniporter-Dependent Energetic Dysfunction Drives Hypertrophy in Heart Failure
Modulation of Phospholipase A<sub>2</sub> Membrane Activity by Anti-inflammatory Drugs
Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice
Primary recovery strategies of low-molecular-weight toxins from <i>Crotalus molossus nigrescens</i> and <i>Crotalus atrox</i> using aqueous two-phase and three-phase partition systems
Synthesis and Characterization of Rutile TiO<sub>2</sub> Nanoparticles for the Toxicological Effect on the H9c2 Cell Line from Rats
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis
Amorphous SiO2 nanoparticles promote cardiac dysfunction via the opening of the mitochondrial permeability transition pore in rat heart and human cardiomyocytes
Resveratrol Prevents Right Ventricle Remodeling and Dysfunction in Monocrotaline-Induced Pulmonary Arterial Hypertension with a Limited Improvement in the Lung Vasculature
Nanoencapsulated Quercetin Improves Cardioprotection during Hypoxia-Reoxygenation Injury through Preservation of Mitochondrial Function
Optimization of PLGA-Resveratrol nanoparticle synthesis through combined response surface methodologies
Plasma protein adsorption on Fe<sub>3</sub>O<sub>4</sub>-PEG nanoparticles activates the complement system and induces an inflammatory response
Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats
Ex Vivo Cardiotoxicity of Antineoplastic Casiopeinas Is Mediated through Energetic Dysfunction and Triggered Mitochondrial-Dependent Apoptosis
Towards reproducible measurement of nanoparticle size using dynamic light scattering: Important controls and considerations

Letter (1)

Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity. Letter regarding the article 'Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis'. Reply

Review (6)

Targeting the mitochondrial Ca<SUP>2+</SUP> uniporter complex in cardiovascular disease
A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety
Modeling and optimization of nanovector drug delivery systems: exploring the most efficient algorithms
A systematic review of post-translational modifications in the mitochondrial permeability transition pore complex associated with cardiac diseases
Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure
Nanomedicine for the cardiac myocyte: Where are we?
22
OMAR LOZANO

Principal investigator

Escuela de Medicina y Ciencias de la Salud

Institute for Obesity Research

México, México

6
Gerardo García

Líder de Unidad de Investigación en Medicina Experimental y Terapías Avanzadas.

InstitutoTecnológico de Monterrey.

Monterrey, México